Key Highlights
- LLY shares started trading at $1,208.37, marking a 14.4% gain year to date and surpassing S&P 500 performance
- GLP-1 medications Mounjaro and Zepbound contributed almost 65% of first-quarter 2026 revenue
- Newly introduced oral GLP-1 treatment Foundayo positions the company for GLP-1 revenues exceeding 65% in the second quarter
- First-quarter earnings per share reached $8.55, surpassing analyst projections of $6.97, while revenue hit $19.80 billionāa 55.5% year-over-year increase
- Strategic acquisitions and collaborations totaling over $20 billion announced throughout 2026 to expand beyond GLP-1 portfolio
Eli Lilly (LLY) shares kicked off Friday’s session at $1,208.37, hovering close to the 52-week peak of $1,238.00. The pharmaceutical giant has delivered a 14.4% return year to date, outstripping the pharmaceutical sector’s 11.6% advance and the broader S&P 500 index.
The Indianapolis-based drugmaker posted first-quarter 2026 earnings of $8.55 per share, significantly exceeding Wall Street’s consensus forecast of $6.97. Total revenue reached $19.80 billion, beating analyst estimates of $17.82 billion and representing a 55.5% jump compared to the prior-year quarter.
The company’s powerhouse GLP-1 treatmentsāMounjaro and Zepboundāwere the primary catalysts behind this impressive performance. These two medications alone accounted for nearly 65% of total first-quarter sales. Following the U.S. commercial rollout of Foundayo, Lilly’s oral GLP-1 therapy designed for obesity treatment, management anticipates GLP-1 products will represent more than 65% of revenue in the second quarter.
The introduction of Foundayo reignites direct market rivalry with Novo Nordisk (NVO), which rolled out its oral Wegovy formulation in January 2026, securing a temporary first-mover advantage.
Strategic Expansion Beyond GLP-1 Portfolio
While GLP-1 medications dominate current sales, Lilly has aggressively pursued diversification to minimize dependence on its obesity and diabetes franchise.
The company’s expanding therapeutic pipeline includes Omvoh for inflammatory bowel conditions, Jaypirca addressing specific hematologic malignancies, Ebglyss approved for atopic dermatitis treatment, Kisunla targeting early-stage Alzheimer’s disease, and Inluriyo recently launched for metastatic breast cancer patients.
Jaypirca has emerged as a standout performer. The FDA broadened its approved indications in late 2025 for patients experiencing relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Subsequently, Europe’s Committee for Medicinal Products for Human Use recommended expanded approval across all CLL treatment lines, with the European Commission’s final determination still forthcoming.
Additionally, Lilly awaits a comparable FDA label expansion decision for Jaypirca later this year. Approval would significantly enlarge the addressable patient population within the United States.
Regarding mergers and acquisitions, Lilly deployed over $20 billion throughout 2026 on strategic transactions encompassing oncology, neuroscience, cardiovascular therapeutics, gene editing technologies, and vaccine development. These investments represent a substantial commitment to long-term portfolio diversification.
Stock Valuation and Wall Street Perspective
At present trading levels, LLY shares command a forward price-to-earnings multiple of 30.67āhigher than the pharmaceutical industry average of 18.76 yet below the company’s five-year historical mean of 34.56. Market capitalization currently stands at $1.14 trillion.
Full-year 2026 earnings per share projections have trended upward during the past 60 days, climbing from $33.86 to $35.67. Looking ahead to 2027, analyst estimates increased from $42.56 to $44.61.
Institutional investors hold 82.53% of outstanding shares. World Investment Advisors expanded its position by 12.1% during the first quarter of 2026, purchasing an additional 2,936 shares to reach a total holding of 27,134.
Wall Street sentiment remains overwhelmingly bullish. Goldman Sachs maintains a buy recommendation with a $1,283 price objective. Jefferies recently elevated its target to $1,350, also maintaining a buy rating. Morgan Stanley reaffirmed its overweight stance in June.
Among 30 analysts monitored by MarketBeat, 23 recommend buying the stock, with an average price target of $1,235.07.
The sole contrarian voice: HSBC downgraded shares to reduce in March, establishing an $850 price target.
Lilly’s fiscal year 2026 guidance projects EPS ranging from $35.50 to $37.00, while the sell-side consensus currently sits at $35.74.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
